Standard BioTools (NASDAQ:LAB) vs. Alternate Health (OTCMKTS:AHGIF) Critical Analysis

Alternate Health (OTCMKTS:AHGIF) and Standard BioTools (NASDAQ:LAB) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Alternate Health and Standard BioTools, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alternate Health	0	0	0	0	0.00
Standard BioTools	1	4	0	0	1.80

Standard BioTools has a consensus target price of $1.35, suggesting a potential upside of 6.30%. Given Standard BioTools’ stronger consensus rating and higher probable upside, analysts clearly believe Standard BioTools is more favorable than Alternate Health.

Profitability

This table compares Alternate Health and Standard BioTools’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alternate Health	N/A	N/A	N/A
Standard BioTools	-86.06%	-20.89%	-15.98%

Institutional & Insider Ownership

53.7% of Standard BioTools shares are held by institutional investors. 23.2% of Standard BioTools shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Alternate Health and Standard BioTools”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alternate Health	N/A	N/A	N/A	N/A	N/A
Standard BioTools	$174.43 million	2.80	-$138.88 million	($0.34)	-3.74

Alternate Health has higher earnings, but lower revenue than Standard BioTools.

Summary

Standard BioTools beats Alternate Health on 5 of the 8 factors compared between the two stocks.

About Alternate Health

Alternate Health Corp., a diversified healthcare company, provides cloud based software solutions in Canada. It offers medical practice and controlled substance management software, blood analysis and toxicology labs, clinical research, continuing education programs, nutraceutical products, and security and control services to the medical cannabis industry. The company is headquartered in Toronto, Canada.

About Standard BioTools

Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.